# Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

> **NCT03696212** · PHASE1,PHASE2 · TERMINATED · sponsor: **Arrys Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Adenocarcinoma

## Interventions

- **DRUG:** grapiprant and pembrolizumab

## Key facts

- **NCT ID:** NCT03696212
- **Lead sponsor:** Arrys Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-08
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.
- **Last updated:** 2021-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696212, "Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03696212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*